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Purpose: Percutaneous transluminal angioplasty (PTA) is an increasingly popular invasive 
treatment for peripheral arterial disease, but there have been very few controlled trials to 
justify its use. This randomized controlled clinical trial was performed to determine in 
patients with mild and moderate intermittent claudication differences in outcome be- 
tween PTA and conventional medical treatment after 2 years. 
Methods: Six hundred patients with claudication were screened at the Peripheral Vascular 
Clinic, Royal Infirmary of  Edinburgh. Sixty-two patients with short femoral artery 
stenoses or occlusions (47 patients) and iliac stenoses (15 patients) were andomized to 
either PTA plus medical treatment (PTA group, 30 patients) or to medical treatment 
alone (control group, 32 patients). Medical treatment consisted of  daily low-dose aspirin 
and advice on smoking and exercise. Outcome measures tudied were patient-reported 
maximum walking distance, exercise treadmill distance until onset of  daudication, tread- 
mill maximum walking distance, ankle-brachial pressure index (ABPI), quality of  life 
(Nottingham Health Profile), and duplex ultrasotmd-measured extent of  occlusive dis- 
ease. 
Results: At 2 years of  follow-up, the PTA group and control subjects did not differ 
significantly in patient-reported maximum walking, treadmill onset to claudication, 
treadmill maximmn walking distances, or ABPI (p > 0.05). However, the PTA group had 
significantly fewer occluded arteries (p = 0.003) and a lesser degree of stenosis (expressed 
in terms of  the velocity ratio; p = 0.004) in patent arteries. Quality of  life was not 
demonstrably different between the two groups (p > 0.05). 
Conclusions: Two years after PTA, patients had less extensive disease than medically 
treated patients, but this did not translate into a significant advantage in terms of  
improved walking or quality of  life. There are important implications for patient man- 
agement and future clinical research. (J Vasc Surg 1997;26:551-7.) 
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The most common invasive treatment for mild- 
and moderate-severity intermittent claudication is 
percutaneous transluminal angioplasty (PTA), and 
yet there are no controlled ata to support he widely 
held assumption that it is o f  lasting benefit to pa- 
tients. PTA has been practiced for 30 years, ~ its use is 
increasing, 2 and the indications for its use are being 
extended. 3 However, the consumption of  resources 
is substantial, 4 and even in the most experienced 
hands it is not without complications,  Despite this, 
there has been a conspicuous lack of  proper con- 
trolled research into its efficacy. In the United King- 
dom there are a number o f  large vascular surgical 
groups, including the Vascular Surgical Society o f  
Great Britain and Ireland and the Joint Vascular 
Research Group, but none has yet taken on the 
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multicenter t ials that would be necessary to provide 
clear answers to the key questions in this area, such as 
whether PTA performed for claudication results in 
fewer reconstructive ascular procedures and ampu- 
tations, and whether PTA is advantageous in terms of 
improved walldng. There have been several leading 
articles that have highlighted the issues at stake, 3,6-8 
but there have been only two small randomized con- 
trolled trials of PTA compared with nonsurgical 
treatment of claudication reported in full in the liter- 
ature. 9-11 In brief, the Oxford trial 9,1° demonstrated 
an early advantage in terms of walking in favor of 
intensive xercise therapy over PTA alone, but this 
difference was lost after several years of follow-up. In 
Edinburgh, 11 early results demonstrated a clear ad- 
vantage after 6 months in favor of PTA in terms of 
improved walldng, ABPI, and pain in a quality-of-life 
score. Another trial from New Zealand, to date only 
published in abstract form, failed to show any advan- 
tage of PTA during 4 years of follow-up. 12 This 
paper reports the results of the Edinburgh trial at 2 
years of follow-up. 
PATIENTS AND METHODS 
Between 1991 and 1993, all patients referred to 
the Peripheral Vascular Clinic at the Royal Infirmary 
of Edinburgh with predominantly unilateral inter- 
mittent claudication were considered for inclusion. 
Exclusion criteria were previous angioplasty or arte- 
rial surgery to the symptomatic leg, myocardial in- 
farction within the previous 6 months, patients tak- 
ing oral anticoagulants, duration of symptoms less 
than 1 month, inability to manage the treadmill test, 
and any psychiatric llness or other reason that would 
make follow-up difficult. 
In the clinic, a history was taken and a physical 
examination was performed by a vascular consultant 
or registrar, and the remaining tests were carried out 
by the vascular technician. Patients were asked to 
estimate their maximum walking distance on the flat 
under normal conditions (reported maximum walk- 
ing distance). A venous blood sample was taken for 
plasma total cholesterol estimation to ensure that the 
two groups would be equally randomized for this 
important variable. After the patient had rested su- 
pine for 10 minutes, right and left brachial and right 
and left ankle systolic pressures were measured using 
Doppler probe and random zero sphygmomanome- 
ter (Hawksley & Son Ltd, Lancing, Surrey, U.K.). 
For each foot in turn, the ankle-brachial pressure 
index (ABPI) was calculated by dividing the highest 
Doppler ankle pressure by the higher of the two 
brachial pressures. Weight and height were measured 
(instrument by Seca-Delta, Germany) in light cloth- 
ing without shoes. Patients completed the Notting- 
ham Health Profile, 13 which enquired about six fac- 
tors of quality of life: pain, mobility, sleep, emotion, 
energy, and isolation. A standard treadmill test (4 
l~n/hr at 10% incline) was performed to measure the 
time to onset of claudication and the time to cessa- 
tion of walking as a result of claudication, up to a 
maximum of 10 minutes. These were converted to 
distances--treadmill onset claudication distance and 
treadmill maximum walking distance, a maximum 
walking time of 10 minutes corresponding to 667 m 
distance on the treadmill. 
The symptomatic leg was examined after rest by 
color duplex using an ATL UM9 (HDI) machine 
(Advanced Technology Laboratories, Bothell, Wash.) 
from common iliac artery origin to distal popliteal 
artery. Lesions considered suitable for PTA were 
discrete femoral or iliac stenoses or femoropopliteal 
occlusions -< 10 cm long. Patients were excluded 
from further study if they were found to have lilac 
occlusion, >10 cm length femoropopliteal occlu- 
sion, multiple stenoses, or diffuse disease with long 
stenoses. Iliac occlusions were excluded because they 
were considered more difficult to screen using du- 
plex, and there was no clear consensus on what 
length of occlusion could reasonably be dilated with 
good results. Patients who had lesions suitable for 
PTA identified on duplex scanning then underwent 
percutaneous transfemoral arteriography. Those 
whose lesions were confirmed as suitable for PTA 
were randomized to either conventional medical 
treatment (low-dose aspirin plus advice on smoking 
and exercise) or PTA by balloon dilatation plus the 
same medical treatment. Arterial stenting was not 
routinely used in the department at the time of this 
study. With regard to exercise, patients were advised 
to continue to walk as far as possible and as fre- 
quently as possible within the limits imposed by pain. 
All were strongly advised to stop smoldng altogether. 
Randomization was by telephone link to a comput- 
erized random allocation system provided by the 
Scottish Cancer Trials Office, University of Edin- 
burgh. In most cases, PTA was carried out in the 
same session as the arteriography. Successful angio- 
plasty was defined as a residual degree of luminal 
narrowing <50%. 
Patients were followed-up 6 months and 2 years 
after randomization. The 6-month follow-up results 
have been reported elsewhere. 11At follow-up, sev- 
ern of the baseline measurements were repeated: 
treadmill exercise test, ABPI, and completion of the 
Nottingham Health Profile questionnaire. Duplex 
JOURNAL OF VASCULAR SURGERY 
Volume 26, Number 4 Whyman et al. 553 
Table I. Baseline characteristics of PTA and control groups 
PTA Control 
(~ = 30) (n = 32) 
Age and Sex 
Mean age in yr (range) 
Men (rio.) 
Cardiovascular Risk Factors 
Current smokers (no.) 
Serum cholesterol--mean (SE) mmol/L 
Systolic blood pressure--mean (SE) mm Hg 
Body mass index--mean (SE) kg/m 2 
Diabetes mellitus (no.) 
Severity of disease 
Reported maximum walking distance inmeters--median (IQR) 
Treadmill distance inmeters until onset claudication--median (IQR) 
Treadmill maximum walking distance inmeters--median (IQR) 
Anlde-brachial pressure index--mean (SE) 
Site and Type of Lesion 
No. of femoral occlusions 
No. of femoral stenoses 
No. ofiliac stenoses 
Duplex velocity ratio of stenoses--median (IQR) 
60.6 (44 to 73) 62.6 (45 to 78) 
23 28 
15 16 
6.69 (0.26) 6.44 (0.33) 
157.9 (4.1) 155.4 (3.5) 
25.78 (0.50) 26.20 (0.70) 
4 1 
200 (100 to 425) 200 (100 to 430) 
56 (33 to 133) 78 (56 to 100) 
228 (77 to 442) 183 (117 to 519) 
0.74 (0.03) 0.71 (0.02) 
7 9 
16 15 
7 8 
4.55 (3.67 to 5.00) 5.33 (3.45 to 7.50) 
(n = 19) (n = 21) 
All differences between PTA and control groups were nonsignificant (p> 0.05). 
IQR, Interquartile range. 
ultrasonography was also carried out to determine 
whether the arterial site in question was patent or 
occluded, and, if patent, to assess the degree of 
sten0sis expressed as the duplex velocity ratio. ~4a 5 
Analysis was carried out using the statistical pack- 
age SPSS-X. In addition to treating them as contin- 
uous variables, the walldng distances were converted 
to binary "variables: reported ability to walk 1 kin; no 
symptoms after 667 m on the treadmill; and ability to 
reach 667 m on the treadmill. X 2 and Fisher's exact 
test were used to examine categorical differences, and 
Student's t test and the Mann-Whimey U test were 
used to examine ordinal differences between the PTA 
and control group at randomization and after 2 
years. Two-tailed p values are given. The sample size 
was calculated as follows: a significant difference be- 
tween two groups of 27 patients hould be detected 
if significant symptomatic mprovement occurred in 
20% of the control group and 60% of the PTA group, 
with a power of 90% and a type I error of 0.05. 
Significant improvement was arbitrarily taken as the 
ability to walk 667 meters (10 minutes) on the tread- 
mill free of pain where this was not possible before. 
Patients in the PTA group who required repeat an- 
gioplasty were included in the final analysis, whereas 
patients in the control group who underwent angio- 
plasty or surgery were excluded from analysis. Ap- 
proval for the trial was obtained in advance from the 
Lothian Research Ethics Sub-Committee for Sur- 
gery. Written consent was obtained from all patients 
who underwent angiography. 
RESULTS 
Approximately 600 patients with claudication 
were seen in the outpatient departmcnt between 
199I and 1993. Of these, 425 were initially consid- 
ered suitable for trial entry and were subjected to 
duplex scanning. Three hundred sixteen patients did 
not fulfill the inclusion criteria on the basis of duplex 
findings, and an additional 15 did not wish to partic- 
ipate in the trial at this stage. The remainder (94 
patients) underwent transfemoral rteriography, af- 
ter which another 32 were excluded from the trial. 
The main reason for exclusion of these patients was 
the finding of more diffuse disease on the angiogram 
than had been predicted on duplex, and even though 
the lesions were still amenable to angioplasty from a 
technical standpoint, hey were not as discrete as we 
thought was necessary for inclusion in the trial. Thus 
62 patients had disease suitable for PTA and were 
randomized. Only one patient had a duration of 
symptoms <3 months at the time of consultation, 
and the median duration was 6 months in the control 
group and 12 months in the PTA group, with no 
significant difference between the groups. The me- 
dian time between consultation and randomization 
was a further 60 days for the control group and 53 
days for the PTA group, increasing still further the 
overall duration of symptoms between onset and 
randomization. 
Randomization. Randomization allocated 30 
patients to the PTA group and 32 to the control 
group. Table I shows the age, sex, occurrence of 
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Table II. Severity of peripheral arterial disease in PTA and control groups at 2 years 
PTA Control 
group group p 
No. with 1 km reported walldng distance 14 of 27 
Reported walldng distance--median (IQR) 999 (250 to 999) 999 
No. without claudication on treadmill exercise 12 of 26 
Treadmill distance until onset claudication--median (IQR) 383 (85-667) 333 
No. walking maximum distance on treadmill exercise 15 of 26 
Treadmill maximum walking distance--median IQR 667 (137 to 667) 600 
Ankle- brachial pressure index--mean (SE) 0.81 (0.03) 0.75 
Number with occlusion 4 of 27 
Duplex velocity ratio--median (IQR) 1.98 (1.47 to 2.94) 3.55 
(n = 22) 
15 of 28 0.898 
(200 to 999) 0.695 
7 of 27 0.125 
(106 667) 0.578 
13 of 27 0.489 
(211 to 667) 0.962 
(0.04) 0.164 
14 of 26 0.003 
(2.64 to 8.34) 0.004 
(n = 10) 
IQR, Interquartile range. 
cardiovascular risk factors, severity of arterial disease, 
and site and types of lesion in the two groups. No 
statistically significant differences were found be- 
tween the two groups (p > 0.05). The length of 
femoral occlusions in both groups was comparable: 
median 3 cm (range, 1 to 10 cm) in the PTA group, 
and median 4 cm (range, 2 to 8 cm) in the control 
group. No patient in either group had a major com- 
plication (defined as needing surgery to correct, or 
prolongation of length of admission) from angiogra- 
phy or angioplasty. 
Follow-up. At 2 years of follow-up, one patient 
in the PTA group had undergone repeat angioplasty 
of the same lesion after a return of claudication to its 
previous level, and no patient deteriorated enough to 
require surgery. In the control group, one patient 
had undergone surgery for marked deterioration of 
symptoms, one had undergone angioplasty for wors- 
ening claudication, and one patient insisted on an- 
gioplasty because there had been o improvement in 
symptoms. Two patients died, one from myocardial 
infarction and the other from rectal cancer (both in 
the control group), and two patients declined to 
attend further follow-up, one because of recent car- 
diac transplantation and the other simply did not 
want to return to he hospital (both in the PTA 
group). In the PTA group, three patients had also 
undergone angioplasty for claudication in the other 
leg within 2 years of randomization. The number of  
patients available for analysis is given in Tables II and 
III. The reasons for incomplete data on the exercise 
treadmill or on duplex scanning was as follows: death 
(causes as above), nonattendance (reasons as above), 
patient's inability to walk well (recent surgery, severe 
angina, new myocardial infarction), temporarily 
faulty treadmill machine, and nonspecific illness. 
Differences in walking and ABPI  between 
PTA and control  groups at 2 years. As shown in 
Table II, there was no statistically significant differ- 
ence between PTA and control patients in patient- 
reported maximum walking, treadmill onset to clau- 
dication, treadmill maximum walking distance, or 
ABPI (p > 0.05). It is not possible to precisely report 
the proportional increase from baseline in walking 
distances in both groups because of the set maximum 
thresholds. However, both PTA and control groups 
reported at least a 400% increasc in walking distance, 
the median treadmill distance to onset of claudica- 
tion in the PTA group increased 580% compared 
with 327% in the control group, and the median 
treadmill maximum walking distance increased at 
least 193% in thc PTA group compared with 228% in 
the control group. The small number of patients with 
iliac lesions does not permit separate analysis by level 
ofdiscase. 
Differences in lesion progression at 2 years. 
As evident from Tables I and II, five new occlusions 
in the control group developed uring follow-up. In 
the PTA group, all seven occlusions were initially 
rendered patent. Two reoccluded, and in another 
two patients new occlusions occurred uring follow- 
up. Thus there were a significantly greater number of 
occluded arteries in the control group (n = 14) than 
in the PTA group (n = 4) at 2 years (p = 0.003). In 
arteries that remained patent, the degree of narrow- 
ing at the stenosis (velocity ratio) was significantly 
less in the PTA group (p = 0.004). In the PTA 
group, all occlusions measured -<10 cm in length, 
whereas in the control group two lesions mcasured 
>10 cm at 2 years so that, in principle, these would 
not have been amenable to angioplasty. 
Differences in quality o f  life at 2 years. The 
number of subjects who responded "yes" to one or 
more questions in each of the six aspects of quality of 
life in the NHP is shown in Table III. At randomiza- 
tion there were no significant differcnces in any of the 
factors between the two groups (p > 0.05). At the 
2-year follow-up there were no differences between 
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Table II I . Nottingham Health Profile scores in PTA and control group at baseline and at 2 years 
Baseline 2 years 
PTA Control PTA Control 
(n = so) (n = 32) p (~ = SO) (n = S2) p 
Energy 8 13 NS 5 of  29 2 of 27 0.266 
Pain 26 29 NS 15 of  29 17 of  27 0.396 
Emotion 10 18 NS 2 of  28 2 of  27 0.537 
Sleep 17 11 NS 10 of 29 9 of 27 0.928 
Isolation 5 4 NS 1 of 29 1 of  27 0.959 
Mobility 16 19 NS 8 of 29 7 of  27 0.889 
Values are the number of  subjects who responded "yes" to one or more questions in each of the six quality of  life indexes. 
n is the total number of  subjects who answered the questions. 
the two groups in any of the quality of life factors 
(p > 0.05). 
DISCUSSION 
This trial has shown that in a select group of 
patients with claudication and relatively discrete il- 
iofemoral disease the addition of angioplasty to con- 
ventional medical treatment does not confer a mea- 
surable benefit in the patient's perceived or measured 
walking ability after 2 years. Neither is there a signif- 
icant difference in ABPI or quality of life a s measured 
by the Nottingham Health Profile between the two 
groups. There was, however, a major difference in 
the number of occlusions and the severity ofstenoses 
between the groups. The latter finding suggests that 
there may be potential for PTA to benefit patients in 
the long term by the need for fewer arterial recon- 
structive procedures and amputations. However, be- 
cause occluded vessels may have a protective ffect on 
the development of atheroma in the distal circula- 
tion, 16 this will remain pure speculation without the 
appropriate clinical studies being carried out. 
An interesting observation in this study is that 
only i0% of all screened patients were ultimately 
suitable for randomization. Clearly, this is a difficult 
disease to study. The diffuse nature ofatherosclerosis 
makes discrete and isolated stenosis or short-segment 
occlusion relatively uncommon findings. However, 
the purpose of studying this subset of patients was to 
make follow-up examination of the involved segment 
of arterial disease easier, with less influence from 
progression of disease in other major segments. Thus 
it is important o bear in mind that the results can 
really only be applied to patients who have a similar 
extent of arterial disease, and that, strictly, one 
should not extrapolate to all patients with claudica- 
tion who have lesions that could be amenable to 
angioplasty. The reasons why the PTA group did not 
have a significantly better outcome than the control 
group are unclear. We did not find major progression 
of disease in other segments, and as judged by the 
data presented here the area of disease under study 
was less severe in the PTA group at follow-up. Per- 
haps the PTA group took less self-imposed exercise 
that was necessary to maintain the early improvement 
in walldng at 6 months. It is possible that there are 
insufficient patients to demonstrate a significant dif- 
ference in walldng between the two groups, that is, a 
type 2 statistical error. This is unlikely to be the case 
because at the 6-month follow-up the difference in 
walking between the two groups was shown to be 
statistically significant. 1 i With a longer follow-up pe- 
riod, the difference has been attenuated. Even if the 
number of patients in the study were larger and a 
statistically significant difference were eventually 
found, the clinical importance attached to the find- 
ings might be considered less because so many pa- 
tients would have to be treated to show a benefit. 
There was, however, a trend for the PTA group to 
have more patients free of claudication (12 of 26) 
compared with the control group (seven of 27), a 
greater treadmill distance until onset of claudication 
(median, 383 vs 333 m), a greater treadmill maxi- 
mum walldng distance (median, 667 vs 600 m), and 
a greater ABPI (0.81 vs 0.75). It is possible that 
within the PTA group there is a subgroup that has 
benefited compared with medical treatment alone, 
for example, patients with a short stenosis in a large 
artery. Another possible reason for there being a 
poor distinction between the groups in terms of 
walldng distances i related to the arbitrary threshold 
of 667 m. One cannot readily distinguish the two 
groups when a significant number of  patients have 
achieved the threshold walking distance, and it is 
possible that given a higher threshold the PTA group 
might have been shown to fare better. However, the 
median distance until onset of claudication differed 
very little between the two groups (383 and 333 m), 
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and probably not enough to constitute a clinically 
important difference. The results from this study do, 
therefore, at the very least suggest the need for larger 
trials. 
Perhaps what is needed is a large trial in which 
patients are stratified according to the type o f  lesion 
present. However,  in the New Zealand study, 12 there 
were no factors identified to indicate a more selective 
approach for long-term success, including run-off, 
type of  lesion <10 cm length, or diabetes. 
There is a striking lack of  controlled data on 
which to base a sound policy for management o f  
patients with claudication. PTA has been practiced, 
in one form or another, for more than 30 years, 1and 
in that time there have been many reports o f  its 
applications in vascular disease, its efficacy, and asso- 
ciated complications. However, we are aware of  only 
three reports o f  randomized controlled trials o f  PTA 
versus nonsurgical treatment, one from Oxford, 9,1° 
the present study whose early results have been pub- 
lished, n and the New Zealand study. ~2 It is notewor- 
flay that, although the designs o f  the two former 
sttidies were very different, in the Oxford study, 
which compared PTA with intensive walking exercise 
therapy, the results beyond 6 months are broadly 
similar, that is, PTA does not afford improved walk- 
ing when compared with intensive exercise or simple 
medical advice and aspirin. In the New Zealand study 
of  100 patients, the PTA and control groups were 
indistinguishable by their postexercise anlde pressure 
measurements after 2 years. More PTA patients re- 
quired intervention for symptom deterioration and 
more deteriorated radiologically, but no statistical 
analysis of  these differences was shown in the pub- 
lished abstract. 
In considering the opt imum treatment for claudi- 
cation, a reduction in the need for amputation and 
reconstructive surgery is o f  paramount importance. 
However, a trial that demonstrates such advantages 
would probably require several thousand patients 
and was beyond the scope of  this study. In addition, 
there are other factors that need to be considered. 
These include the immediate risk o f  'PTA, its con- 
sumption of  resources, patient discomfort and incon- 
venience, the late impact on progression of  disease 
with any method of  intervention, and perhaps the 
ability to modify other cardiovascular risk factors 
such as body weight by improved exercise. Clearly, 
these hypotheses have not been tested in this trial, 
aaad more detailed studies would be required to ex- 
plore this area. 
The message could not be simpler--large-scale 
randomized controlled trials are necessary to demon- 
strate which, if any, patients might benefit from PTA. 
Improved patient selection could lead to consider- 
able cost savings, and resources might accordingly be 
reallocated. 
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